Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers.
Hodges HC, Stanton BZ, Cermakova K, Chang CY, Miller EL, Kirkland JG, Ku WL, Veverka V, Zhao K, Crabtree GR
Nat Struct Mol Biol. 2018 Jan;25(1):61-72. doi: 10.1038/s41594-017-0007-3. Epub 2017 Dec 11. PubMed
Hodges HC, Stanton BZ, Cermakova K, Chang CY, Miller EL, Kirkland JG, Ku WL, Veverka V, Zhao K, Crabtree GR
Nat Struct Mol Biol. 2018 Jan;25(1):61-72. doi: 10.1038/s41594-017-0007-3. Epub 2017 Dec 11. PubMed
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 107056 | WT Smarca4-sfGFP | Expression of wild-type Smarca4 (Brg1) with C-terminal super-folder GFP fusion. |
| 107057 | K785R Smarca4-sfGFP | Expression of dominant-negative K785R Smarca4 (Brg1) with C-terminal super-folder GFP fusion. |
| 107058 | WT Smarca4-V5 IRES-puro | Expression of wild-type Smarca4 (Brg1)-V5 fusion with IRES puromycin resistance. |
| 107059 | K785R Smarca4-V5 IRES-puro | Expression of dominant-negative K785R Smarca4 (Brg1)-V5 fusion with IRES puromycin resistance. |